MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/21532176261454487

Медицинская библиотека · Childhood obesity (Print) · 2026

Cost-Effectiveness of Access to Obesity Care and Treatments for Adolescents.

Doan Tran T, Mueller Heeseung J, Avanceña Anton L V, Peyyety Vaishnavi, Bensignor Megan O, Vajravelu Mary Ellen

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Inadequate care access may exacerbate the childhood obesity epidemic. Obesity treatments are recommended for adolescents, but the health-economic impacts of unequal treatment access are unclear. This study aims to evaluate the cost-effectiveness of improving access levels to adolescent obesity care and treatment.

METHODS

In this economic evaluation, we used a decision-analytic model to simulate a synthetic cohort of 1000 US adolescents from ages 12 to 26 on an annual basis. Modeled treatment strategies included phentermine-topiramate, semaglutide, bariatric surgery, and lifestyle modification (usual care). Primary analysis modeled perfect care access for reproducibility with prior studies. Secondary analyses modeled imperfect access to primary care visits, specialty visits, and treatment initiation among distinct groups by insurance coverage or race and ethnicity. Uncertainty analyses tested model parameter estimates. Outcomes were costs, health effects [averted obesity cases, quality-adjusted life years (QALYs)], and incremental cost-effectiveness ratios (ICERs) from health care sector and limited societal perspectives, including caregiver time.

RESULTS

Phentermine-topiramate (vs. lifestyle) yielded an ICER of 2025 US$112,141/QALY, and semaglutide (vs. phentermine-topiramate) yielded $166,513/QALY under perfect access. Under imperfect access, cost-effectiveness and health gains were reduced. Cost-effectiveness was reduced by 11%, and averted obesity cases decreased from 57% to 3% for semaglutide. Health gains were lowest in Medicaid-insured, Black, or Hispanic youth. ICERs were sensitive to medication characteristics (costs, efficacy, discontinuation) and health utilities.

CONCLUSIONS

In this economic evaluation, phentermine-topiramate and semaglutide were cost-effective under $200,000/QALY, using 2025 pricing. Care access disparities limit health-economic gains for adolescents. Improving care access is critical to addressing the childhood obesity epidemic.

Для цитирования: Doan Tran T, Mueller Heeseung J, Avanceña Anton L V, Peyyety Vaishnavi, Bensignor Megan O, Vajravelu Mary Ellen. Cost-Effectiveness of Access to Obesity Care and Treatments for Adolescents.. Childhood obesity (Print). 2026. DOI: 10.1177/21532176261454487.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.